Focus V has shown limited PFS benefit, a high incidence of AEs, and no demonstrated improvement in overall survival.

Annual Meeting, held 30 May-3 June 2025, primary results were presented from the ASCENT-04/KEYNOTE-D19 study investigating ...

Johnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer ...

The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other ...

Diakonos Oncology has closed a $20m private placement of Simple Agreements for Future Equity (SAFE) for its Phase II trial of ...

After Lykos' rejection from the FDA last year, companies trying to navigate the psychedelic drug trial sector face various ...

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

Entrada has secured the authorisation within the EU Clinical Trial Regulation to begin the Phase I/II trial of ENTR-601-45.

Biohaven has started a randomised Phase II/III trial of the TYK2 / JAK1 inhibitor, BHV-8000, aimed at treating early ...